You are here

OSE Immunotherapeutics

Boehringer outlines up to $33.6m for cancer asset from OSE Therapeutics

Clinical Trials Arena

Thu, 05/23/24 - 09:43 pm

Boehringer Ingelheim

OSE Immunotherapeutics

Boehringer pays OSE $42M to expand collab into cardio disease, grab new asset

Fierce Biotech

Wed, 05/22/24 - 11:31 am

Boehringer Ingelheim

OSE Immunotherapeutics

cardiovascular disease

AbbVie Puts Potential $713M on the Line for OSE’s Inflammation Antibody

BioSpace

Wed, 02/28/24 - 11:12 am

OSE Immunotherapeutics

monoclonal antibodies

5 Cancer Vaccines to Watch in 2024

BioSpace

Mon, 11/20/23 - 10:15 am

Moderna Therapeutics

pancreatic cancer

OSE Immunotherapeutics

non-small cell lung cancer

Nykode Therapeutics

cervical cancer

An In-Depth Look at Innovation on Cancer Research Day

BioSpace

Sun, 09/26/21 - 11:24 pm

Celyad Oncology

Fore Biotherapeutics

X4 Pharmaceuticals

Elicio Therapeutics

OSE Immunotherapeutics

ASCO: Boehringer, OSE offer promising glimpse of the immuno-oncology drug at the heart of their $1.4B deal

Fierce Biotech

Fri, 05/21/21 - 11:52 am

Boehringer Ingelheim

OSE Immunotherapeutics

immuno-oncology